At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
KSL-Wdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population
U.S. Army Medical Research and Development Command·interventional·Posted Aug 12, 2016·Updated Jul 15, 2025
In Brief
A Phase 2 clinical trial evaluating KSL-W for Plaque Regrowth. Completed, enrolled 27 participants.
Detailed Summary
The Safety, efficacy and tolerability of an Antimicrobial Chewing Gum Formulation in Reducing Dental Plaque
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Regrowth
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionNov 2016
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartOct 1, 2016
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.9 years ago
Interventions
KSL-Wdrug
Antimicrobial KSL-W Plaque reducing chewing gum